Dyfyniad APA

Chen, E. C., Fathi, A. T., & Brunner, A. M. (2018). Reformulating acute myeloid leukemia: Liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Onco Targets Ther.

Dyfyniad Arddull Chicago

Chen, Evan C., Amir T. Fathi, and Andrew M. Brunner. "Reformulating Acute Myeloid Leukemia: Liposomal Cytarabine and Daunorubicin (CPX-351) As an Emerging Therapy for Secondary AML." Onco Targets Ther 2018.

Dyfyniad MLA

Chen, Evan C., Amir T. Fathi, and Andrew M. Brunner. "Reformulating Acute Myeloid Leukemia: Liposomal Cytarabine and Daunorubicin (CPX-351) As an Emerging Therapy for Secondary AML." Onco Targets Ther 2018.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.